2016
DOI: 10.1111/trf.13605
|View full text |Cite
|
Sign up to set email alerts
|

Postnatal cytomegalovirus infection: a pilot comparative effectiveness study of transfusion safety using leukoreduced‐only transfusion strategy

Abstract: BACKGROUND The optimal mitigation strategy to prevent transfusion transmission of cytomegalovirus (TT-CMV) in preterm very low birthweight infants remains debated. Hospitals caring for this patient population have varied practices. STUDY DESIGN AND METHODS A prospective observational comparative effectiveness pilot study was conducted to determine the feasibility for a larger study. The pilot was carried out at hospitals using a leukoreduction (LR)-only transfusion strategy. Specimen and data collection for … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

1
31
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
4
2
1

Relationship

0
7

Authors

Journals

citations
Cited by 31 publications
(32 citation statements)
references
References 21 publications
1
31
0
Order By: Relevance
“…However, Delaney et al recently published the findings of a pilot study of LR-only transfusion in VLBW infants using a similar cohort design to the previous study by Josephson et al so that the results of the two studies might be compared. 79 This small study detected no cases of TT-CMV infection using the LR-only approach (0 of 8; 95% CI =0%-25.3%) although the …”
Section: Prevention Of Transfusion-transmitted Cytomegalovirusmentioning
confidence: 99%
See 2 more Smart Citations
“…However, Delaney et al recently published the findings of a pilot study of LR-only transfusion in VLBW infants using a similar cohort design to the previous study by Josephson et al so that the results of the two studies might be compared. 79 This small study detected no cases of TT-CMV infection using the LR-only approach (0 of 8; 95% CI =0%-25.3%) although the …”
Section: Prevention Of Transfusion-transmitted Cytomegalovirusmentioning
confidence: 99%
“…Since the rate of TT-CMV would be expected to be very low in both the groups, such a trial would require the enrollment of a large number of susceptible infants in order to achieve statistical power to detect a significant difference between the two approaches. 78,79 This fact, combined with the expense of conducting such a study, makes it unlikely that a randomized controlled trial will ever be performed. However, Delaney et al recently published the findings of a pilot study of LR-only transfusion in VLBW infants using a similar cohort design to the previous study by Josephson et al so that the results of the two studies might be compared.…”
Section: Prevention Of Transfusion-transmitted Cytomegalovirusmentioning
confidence: 99%
See 1 more Smart Citation
“…Unfortunately, that study was not designed to concurrently compare the prevention of TTCMV by leukocyte reduction versus CMV sero/antibody testing alone. However, in this issue of TRANSFUSION , investigators from the “belt‐and‐suspenders” study joined forces with investigators from another institution to compare the results of TTCMV prevention using leukocyte‐reduction alone according to a study that was designed to be as comparable as possible at the two institutions . Results from the two studies were identical, and neither detected a single case of TTCMV, whether prevented either by leukocyte‐reduction alone or by the combined approach of leukocyte‐reduction of CMV sero/antibody‐negative blood products …”
mentioning
confidence: 99%
“…In their report on a randomized observational study in this issue of TRANSFUSION , Delaney and colleagues show that the leukocyte‐reduction alone approach completely prevented TTCMV in VLBW preterm infants . Three other nonrandomized observational studies indicated that leukocyte reduction alone strikingly reduced or completely prevented TTCMV in hematopoietic progenitor cell (HPC) transplant recipients, and all three of those reports recommended against the use of blood from CMV sero/antibody‐negative donors—favoring the selection of leukocyte‐reduced blood alone to prevent TTCMV in HPC transplant recipients .…”
mentioning
confidence: 99%